Nuvalent reports Q1 net loss of $44.5M; cash $691.8M; pipeline milestones on track

Nuvalent, Inc.

2024-Q1 EPS reported -$0.69

Q1 2024 net loss of $44.5M; R&D expense $38.6M, G&A $14.0M.
Cash, cash equivalents and marketable securities $691.8M as of March 31, 2024; runway into 2027.
Updated data from ARROS-1 (ROS1) and ALKOVE-1 (ALK) trials expected at a medical meeting in H2 2024.
Phase 1 trial for HER2 program (NVL-330) expected to initiate in 2024.
Plans to outline front-line development strategy for ALK program in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Nuvalent, Inc. reported first quarter 2024 results: net income Net loss was $44.5 million for the first quarter of 2024..

Period: first quarter 2024
Net income: Net loss was $44.5 million for the first quarter of 2024.
Result: reported results

Exact text from the filing

Net loss was $44.5 million for the first quarter of 2024.

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

Nuvalent, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-056223

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.